| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/03/2003 | WO2003026584A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 04/03/2003 | WO2003026581A2 Pharmaceutical compositions and methods for treating cancer |
| 04/03/2003 | WO2003026574A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| 04/03/2003 | WO2003026573A2 Screening and selection methods for statin drug combinations |
| 04/03/2003 | WO2003026570A2 Reduced toxicity cisplatin formulations and methods for using the same |
| 04/03/2003 | WO2003026568A2 Androstanes as androgen receptor modulators |
| 04/03/2003 | WO2003026567A2 Use of neuraminidase inhibitors to prevent flu associated bacterial infections |
| 04/03/2003 | WO2003026564A2 Pharmaceutical compositions for the treatment of urinary disorders |
| 04/03/2003 | WO2003026558A2 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits |
| 04/03/2003 | WO2003026492A2 Prevention and treatment of restenosis by local administration of drug |
| 04/03/2003 | WO2003026479A2 Methods of suppressing microglial activation |
| 04/03/2003 | WO2003026408A1 Model animal with overexpression of regucalcin |
| 04/03/2003 | WO2003002722A3 T cell regulatory genes and methods of use thereof |
| 04/03/2003 | WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 04/03/2003 | WO2002099052A3 Opns as modifiers of the p53 pathway and methods of use |
| 04/03/2003 | WO2002099051A3 Nits as modifiers of the p53 pathway and methods of use |
| 04/03/2003 | WO2002092049A3 System for delivering cosmetics and pharmaceuticals |
| 04/03/2003 | WO2002092016A3 Therapeutic use of rank antagonists |
| 04/03/2003 | WO2002089736A3 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| 04/03/2003 | WO2002085296A3 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| 04/03/2003 | WO2002076460A3 Use of propentofylline to control intraocular pressure |
| 04/03/2003 | WO2002073213A3 Assay |
| 04/03/2003 | WO2002070559A3 Nuclear hormone receptor ligand binding domains |
| 04/03/2003 | WO2002057413A3 Peptides for activation and inhibition of delta pkc |
| 04/03/2003 | WO2002056753A3 P27 prevents cellular migration |
| 04/03/2003 | WO2002049694A3 Sterile bicarbonate-free dialysis concentrate solutions |
| 04/03/2003 | WO2002042444A8 Fungal gene cluster associated with pathogenesis |
| 04/03/2003 | WO2002034248A3 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION |
| 04/03/2003 | WO2002032414A3 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/03/2003 | WO2002022174A9 A novel cationic lipopolymer as biocompatible gene delivery agent |
| 04/03/2003 | WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents |
| 04/03/2003 | WO2002013808A3 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 04/03/2003 | WO2002011703A9 Hybrid neuroprosthesis for the treatment of brain disorders |
| 04/03/2003 | WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 04/03/2003 | WO2002000860A3 Novel proteases |
| 04/03/2003 | US20030065040 Hypotensive agents |
| 04/03/2003 | US20030065038 Administering N-propargyl-1-aminoindan |
| 04/03/2003 | US20030065028 Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| 04/03/2003 | US20030065026 Synergistic mixture with metal compound |
| 04/03/2003 | US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 04/03/2003 | US20030065017 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists / antagonists, estrogens and progestins |
| 04/03/2003 | US20030065015 Enzyme inhibitors; nervous system disorders |
| 04/03/2003 | US20030065008 Hormone replacement therapy; side effect reduction |
| 04/03/2003 | US20030065002 Analgesics; side effect reduction |
| 04/03/2003 | US20030064996 Anticarcinogenic agents, antiinflammatory agents, anticholesterol agents, antidiabetic agents |
| 04/03/2003 | US20030064974 Cognition activator; binding of cortisol to receptor |
| 04/03/2003 | US20030064973 Sexual disorders |
| 04/03/2003 | US20030064967 Using probucol ester |
| 04/03/2003 | US20030064958 Pharmaceutical compositions and methods relating to fucans |
| 04/03/2003 | US20030064957 Reduced toxicity; enhance efficiency; side effect reduction |
| 04/03/2003 | US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| 04/03/2003 | US20030064942 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| 04/03/2003 | US20030064935 Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| 04/03/2003 | US20030064934 Concurrent administering of druh and hypotonic sugar solution |
| 04/03/2003 | US20030064929 Modulating body/cranial hair growth |
| 04/03/2003 | US20030064913 Administering a an inhibitor of nuclear factor-kappa B to an individual undergoing or preparing to undergo a treatment for cancer; particularly ulcerative mouth tissue; antiinflammatory agents; side effect reduction |
| 04/03/2003 | US20030064514 Oligonucleotide for use as antiproliferative agent |
| 04/03/2003 | US20030064493 Methods and means for modulating PGE synthase activity |
| 04/03/2003 | US20030064475 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof |
| 04/03/2003 | US20030064470 Ligand for use as tool in the treatment of tumors in humans |
| 04/03/2003 | US20030064430 Novel steroid-activated nuclear receptors and uses therefor |
| 04/03/2003 | US20030064426 Expression vector for use in the treatment of cancer and age-related defects |
| 04/03/2003 | US20030064385 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 04/03/2003 | US20030064383 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer |
| 04/03/2003 | US20030064374 Detecting neuronal stress in humans; obtain sample, measure phosphodiesterase concentration, evaluate for neuronal stress |
| 04/03/2003 | US20030064122 Pharmaceutical compound, and an amount of a capsaicin compound to deter intranasal, oral, and intravenous abuse while having little or no irritating effect when administered orally or transdermally as directed |
| 04/03/2003 | US20030064121 For use as dietary supplement, in drugs, soy protein concentrate |
| 04/03/2003 | US20030064120 Method for relaxing human beings using personal care compositions |
| 04/03/2003 | US20030064104 Shelf-stable, ready to use; to enhance delivery of active medicants/ingredients of pharmaceuticals, nutraceuticals, dietary supplements, therapeutics, diagnostics |
| 04/03/2003 | US20030064102 Antimicrobial Composition |
| 04/03/2003 | US20030064100 Metronidazole antibiotic product, use and formulation thereof |
| 04/03/2003 | US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/03/2003 | US20030064095 Microfabricated nanopore device for sustained release of therapeutic agent |
| 04/03/2003 | US20030064094 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD) |
| 04/03/2003 | US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion |
| 04/03/2003 | US20030064085 Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent |
| 04/03/2003 | US20030064076 Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food |
| 04/03/2003 | US20030064067 Inducing differentiation and/or promoting proliferation of regulatory T cells, comprising allowing a CD3 agonist and a 4C8 antigen agonist to act on an immunocyte expressing CD3 and 4C8 antigens |
| 04/03/2003 | US20030064049 Topical anti-cancer compositions and methods of use thereof |
| 04/03/2003 | US20030064029 Use of a bioactive agent in manufacture of a medicament for pulmonary delivery whereby medicament comprises perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament |
| 04/03/2003 | CA2463039A1 1,6-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461903A1 Monobactam antibacterial compounds and methods of use thereof |
| 04/03/2003 | CA2461861A1 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 04/03/2003 | CA2461853A1 Anti-fusion assay |
| 04/03/2003 | CA2461731A1 Pharmaceutical compositions for the treatment of urinary disorders |
| 04/03/2003 | CA2461705A1 Coadministration of transport protein with conjugated cobalamin to deliver agents |
| 04/03/2003 | CA2461454A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 04/03/2003 | CA2461372A1 Dna sequences for human angiogenesis genes |
| 04/03/2003 | CA2461345A1 Use of pyy or agonist thereof to modify feeding behaviour |
| 04/03/2003 | CA2461312A1 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits |
| 04/03/2003 | CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses |
| 04/03/2003 | CA2461219A1 Reduced toxicity cisplatin formulations and methods for using the same |
| 04/03/2003 | CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| 04/03/2003 | CA2461136A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 04/03/2003 | CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461042A1 Process for the preparation of fast dissolving dosage form |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2460787A1 Prevention and treatment of restenosis by local administration of drug |
| 04/03/2003 | CA2460344A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |